NCT07112235View on ClinicalTrials.gov

Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets

Not yet recruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

August 18, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
COPD (Chronic Obstructive Pulmonary Disease)Rhinovirus InfectionExacerbation of COPD
Interventions
BIOLOGICAL

Rhinovirus-A16

Nasal inoculation with a dose equivalent to 100 TCID50 of rhinovirus-A16 inoculum will be administered to all participants in the study

Trial Locations (1)

Unknown

Imperial College Healthcare NHS Trust, London

All Listed Sponsors
collaborator

Imperial College Healthcare NHS Trust

OTHER

lead

Imperial College London

OTHER

NCT07112235 - Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic Targets | Biotech Hunter | Biotech Hunter